Biosimilarity: The FDA Perspective - Niazi, Sarfaraz K. (Therapeutic Proteins International, LLC, USA) - Books - Taylor & Francis Inc - 9781498750394 - July 25, 2018
In case cover and title do not match, the title is correct

Biosimilarity: The FDA Perspective 1st edition

Niazi, Sarfaraz K. (Therapeutic Proteins International, LLC, USA)

Price
A$ 385.99
excl. VAT

Ordered from remote warehouse

Expected delivery Jun 5 - 17

Our customers say:

14-day return policy in accordance with European consumer protection law
Top ranking on Trustpilot
Add to your iMusic wish list

Biosimilarity: The FDA Perspective 1st edition

The focus of this book is on how the US FDA will approve biosimilar drugs. The European scene is well developed with specific guidelines that are already in place. However, these guidelines do not apply to the thinking of the FDA in approving these products.

456 pages, 79 colour illustrations, 43 black & white tables

Media Books     Hardcover Book   (Book with hard spine and cover)
Released July 25, 2018
ISBN13 9781498750394
Publishers Taylor & Francis Inc
Pages 398
Dimensions 261 × 187 × 29 mm   ·   1.10 kg
Language English  
Show all

More by Niazi, Sarfaraz K. (Therapeutic Proteins International, LLC, USA)

See all of Niazi, Sarfaraz K. (Therapeutic Proteins International, LLC, USA) ( e.g. Paperback Book and Hardcover Book )